 |
|
multitargeted receptor tyrosine kinase inhibitor ABT-869
An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor ABT-869 inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, ABT-869 may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | ABT-869 | | | | Chemical structure name: | | N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea | | |
|
|
